| Industry payments to pathologists in the USA between 2013 and 2021 A Murayama, S Hirota Journal of Clinical Pathology 76 (8), 566-570, 2023 | 16 | 2023 |
| Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance Y Saiki, S Hirota, A Horii Cancer Drug Resistance 3 (4), 819, 2020 | 13 | 2020 |
| Ablation of dual specificity phosphatase 6 protects against non-alcoholic fatty liver disease via CYP4A and MAPK C Jiang, Y Saiki, S Hirota, K Iwata, X Wang, Y Ito, K Murakami, T Imura, ... The American Journal of Pathology, 2023 | 2 | 2023 |
| Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs Y Yoshida, T Zheng, W Tanabe, F Tomoike, F Hashiya, T Suzuki, S Hirota, ... ChemMedChem 17 (17), e202200188, 2022 | | 2022 |
| Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs … Y Yoshida, T Zheng, W Tanabe, F Tomoike, F Hashiya, T Suzuki, S Hirota, ... ChemMedChem 17 (17), e202200450, 2022 | | 2022 |
| Exploration for possible mechanisms for acquisition of chemoresistance against gemcitabine in pancreatic cancer T Hiyoshi, Y Saiki, S Hirota, K Ishizawa, A Hirayama, T Soga, T Furukawa, ... CANCER SCIENCE 112, 914-914, 2021 | | 2021 |
